Evaluation of injectable robenacoxib for the treatment of post-operative pain in cats: results of a randomized, masked, placebo-controlled clinical trial.
BACKGROUND
Few pharmaceuticals are registered in cats for the management of post-operative pain and inflammation. The objective of this study was to assess the field efficacy and safety of an injectable formulation of the nonsteroidal anti-inflammatory drug robenacoxib in cats undergoing surgery. The study was a multi-center, prospective, randomized, masked, parallel-group, placebo-controlled clinical trial. A total of 349 cats were enrolled and underwent surgery comprising forelimb onychectomy, as an example of orthopedic surgery, plus either ovariohysterectomy or castration. All cats received butorphanol prior to anesthesia and forelimb four-point regional nerve blocks with bupivacaine after induction of general anesthesia. Cats were randomized to receive daily subcutaneous (s.c.) injection of robenacoxib, at a target dosage of 2.0 mg/kg (n = 174), or placebo (n = 175) once prior to surgery and for an additional two days post-operatively.


RESULTS
Significantly (P = 0.037) fewer cats administered robenacoxib received additional analgesia rescue therapy (34 of 173, 19.7 %) compared to cats given placebo (73 of 175, 41.7 %). The percentage of treatment success was therefore 80.3 % with robenacoxib and 58.3 % with placebo. Behavior, posture, pain on palpation of the paw and soft tissue surgery sites, and overall pain were significantly (P < 0.05) improved versus placebo at various time points within the first 8 h in cats receiving robenacoxib. The most frequently reported adverse events were incision site infection/dehiscence, bleeding, vomiting, decreased appetite and lethargy. Frequencies of reported adverse clinical signs, hematology, serum chemistry and urinalysis variables, and body weight changes were similar between groups. There were no significant changes from baseline with robenacoxib in hepatic, hematological or renal clinical pathology variables.


CONCLUSIONS
Robenacoxib by s.c. injection was effective and well tolerated in the control of post-operative pain associated with orthopedic, ovariohysterectomy and castration surgery in cats.
Elanco Animal Health, Companion Animal Development, Greensboro, NC, 27408, USA.
Stephen
S
King
Elanco Animal Health, Companion Animal Development, Greensboro, NC, 27408, USA.
Elizabeth S
ES
Roberts
Elanco Animal Health, Companion Animal Development, Basel, CH-4058, Switzerland. jonathan.king@elanco.com.
Jonathan N
JN
King
Cat; Injectable; NSAID; Pain; Post-operative; Randomized; Robenacoxib
BMC Vet Res. 2015 Mar 26;11:79
25880535
J Am Vet Med Assoc. 2005 Mar 15;226(6):913-9
15786993
J Am Vet Med Assoc. 2000 Oct 1;217(7):1013-20
11019707
Vet J. 2012 Jul;193(1):114-8
22227226
Inflamm Res. 2005 Sep;54(9):358-66
16273333
J Small Anim Pract. 2000 Oct;41(10 ):447-50
11072912
Vet Anaesth Analg. 2007 Jul;34(4):228-50
17451496
J Feline Med Surg. 2006 Feb;8(1):15-21
16213762
J Am Vet Med Assoc. 2002 Apr 1;220(7):1020-4
12420780
Vet Surg. 1994 Jul-Aug;23(4):274-80
8091630
J Feline Med Surg. 2016 Aug;18(8):632-42
26058587
J Vet Pharmacol Ther. 2012 Jun;35(3):290-300
21736587
J Am Vet Med Assoc. 1998 Jul 15;213(2):246-50
9676597
J Vet Intern Med. 2004 Mar-Apr;18(2):190-5
15058769
ISRN Vet Sci. 2012 Jul 01;2012:794148
23738129
J Vet Pharmacol Ther. 2012 Feb;35(1):19-32
21767277
J Am Vet Med Assoc. 2002 Sep 1;221(5):651-3
12216902
J Vet Pharmacol Ther. 2010 Oct;33(5):444-52
20840388
J Am Vet Med Assoc. 2002 Jul 15;221(2):215-22
12118583
J Biopharm Stat. 2011 Mar;21(2):311-25
21391004
J Am Vet Med Assoc. 2006 Jan 1;228(1):65-8
16426168
J Vet Pharmacol Ther. 2009 Feb;32(1):18-30
19161452
Vet Clin North Am Small Anim Pract. 2005 Jan;35(1):129-46
15627631